To characterize the inflammatory myopathy associated with programmed cell death 1 inhibitors (PD-1 myopathy)
Latest Information Update: 28 Jul 2020
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer; Non-small cell lung cancer
- Focus Adverse reactions
- 28 Jul 2020 New trial record